AF
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials : results from the Pembro-real 5Y global registry | Journal for immunotherapy of cancer |  | 2025 | 3 | 1 | ||
| Metastatic gastric cancer : synergizing and sequencing targeted therapy with first-line immunotherapy | Immunotherapy |  | 2024 | 2 | 0 | ||
| Management of stage III non-small-cell lung cancer : rays of hope | Exploration of targeted anti-tumor therapy | | 2024 | 27 | 10 | ||
| Oncogenic alterations in advanced NSCLC : a molecular super-highway | Biomarker research | | 2024 | 25 | 25 | ||
| Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer | Clinical medicine insights. Oncology | | 2023 | 56 | 39 | ||
| Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer | Translational lung cancer research | | 2023 | 54 | 8 | ||
| The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma | Journal of clinical medicine | | 2023 | 23 | 13 | ||
| Precision oncology in advanced non-small cell lung cancer in 2022: a narrative review | | 2023 | 74 | 123 | |||
| Current approaches to neoadjuvant immunotherapy in resectable non-small cell lung cancer | Current oncology reports | | 2023 | 53 | 15 | ||
| Neoadjuvant immunotherapy : a promising new standard of care | International journal of molecular sciences | | 2023 | 67 | 35 | ||
| Novel targets for immune-checkpoint inhibition in cancer | Cancer treatment reviews | | 2023 | 43 | 27 | ||
| RET aberrant cancers and RET inhibitor therapies : Current state-of-the-art and future perspectives | Pharmacology & therapeutics | | 2023 | 29 | 35 | ||
| Pleural mesothelioma in the era of immunotherapy | Clinical medicine insights. Oncology | | 2023 | 25 | 18 | ||
| Cellular therapy in NSCLC : between myth and reality | Current oncology reports | | 2023 | 21 | 14 | ||
| Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer | iScience | | 2022 | 184 | 90 | ||
| The Landscape of Immunotherapy Resistance in NSCLC | Frontiers in oncology | | 2022 | 90 | 56 | ||
| Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study | Translational lung cancer research | | 2022 | 40 | 20 | ||
| SARS-CoV-2 Evolution among Oncological Population: In-Depth Virological Analysis of a Clinical Cohort | Microorganisms | | 2021 | 147 | 82 | ||
| The impact of variant allele frequency in EGFR mutated NSCLCc patients on targeted therapy | Frontiers in Oncology | | 2021 | 323 | 109 | ||
| COVID-19 and lung cancer: risks, mechanisms and treatment interactions | Journal for immunotherapy of cancer | | 2020 | 43 | 9 | ||
| Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer | Cancer Genomics & Proteomics | | 2020 | 173 | 61 | ||
| Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes | Scientific Reports | | 2020 | 289 | 286 | ||
| Tissue-plasma TMB comparison and plasma TMB monitoring in patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors | Frontiers in Oncology | | 2020 | 259 | 210 | ||
| Mutations constitutionnelles BRCA1/BRCA2 et hématotoxicité chimio-induite chez les patientes avec un cancer du sein | | 2020 | 459 | 93 | |||
| Facteurs de croissance granulocytaire dans le traitement curatif desneutropénies fébriles | Revue médicale suisse | | 2020 | 250 | 0 | ||
| Targeted Therapies in Early Stage NSCLC : Hype or Hope? | International journal of molecular sciences | | 2020 | 42 | 35 | ||
| Prostate cancer nonascitic peritoneal carcinomatosis after robot-assisted laparoscopic radical prostatectomy: 3 case reports and review of the literature | Urology | | 2020 | 281 | 0 | ||
| BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients | Breast Cancer Research and Treatment | | 2019 | 392 | 3 | ||
| Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists | Canadian Journal of Cardiology | | 2018 | 495 | 2 | ||
| Chimiothérapie de maintenance : futile ou utile ? | Revue médicale suisse | | 2015 | 446 | 157 |
